Thymulin peptide reverses age-related inflammation, restores cancer immunotherapy in mice

The thymus gland, that small organ behind the breastbone that shrinks as we age, may hold a key to why cancer immunotherapy works less well in older people. Researchers have discovered that a peptide derived from the thymus—called thymulin—can reverse a specific kind of age-related inflammation that interferes with the body's ability to fight tumors, at least in mice.

The problem starts with immune cells called myeloid cells. In younger people, these cells help control inflammation and present antigens to T cells, priming them to attack cancer. But in older people, something shifts. The myeloid cells in and around tumors become increasingly inflammatory, pumping out cytokines like tumor necrosis factor-alpha and interleukins that actually accelerate cancer growth. When researchers compared blood samples from people aged 21 to 33 with those from people aged 60 to 87, the pattern was unmistakable: the older group had far more of these inflammatory myeloid cells, and their tumor-infiltrating immune cells showed elevated expression of inflammatory genes. In aged mice with breast tumors, this inflammatory myeloid profile was associated with faster disease progression and worse survival.

The researchers, publishing their work in Nature Communications, used an elegant experimental approach to trace where this age-related inflammation comes from. They surgically joined young and old mice to share a common bloodstream—a technique called heterochronic parabiosis—and found that circulating factors from young mice could suppress the inflammatory activation in older mice. This suggested that something in young blood was protective. Through pathway analysis, they identified thymulin as a candidate. The peptide, which naturally declines with age, appeared to work by blocking a molecular signaling pathway called NF-κB, which drives the production of inflammatory cytokines.

When the team treated aged mice with thymulin for just one week, the frequency of inflammatory myeloid cells in their bloodstream dropped noticeably. In laboratory experiments with immune cells from aged mice, thymulin suppressed cytokine production and reduced NF-κB activity. More importantly, the peptide enhanced the activity of tumor-fighting T cells and, in a finding with direct clinical relevance, restored the effectiveness of anti-PD-L1 immunotherapy—a class of cancer drugs that work by releasing the brakes on the immune system. Aged mice treated with thymulin and anti-PD-L1 drugs showed better tumor control and longer survival than aged mice receiving either treatment alone.

The human data supported the mouse findings. Analysis of single-cell RNA sequencing from 26 primary breast tumors showed that myeloid cells from older patients carried a distinctly inflammatory gene signature compared to those from younger patients. The researchers also found that genes involved in regulating this inflammaging process—FOXO3, LMNA, and SIRT family genes—are known to be involved in thymic function, suggesting that the thymus gland itself may be orchestrating this age-related shift in myeloid cell behavior.

What makes this work potentially significant is that it identifies a specific, targetable mechanism underlying a real clinical problem: older cancer patients often respond poorly to immunotherapy. If thymulin can be developed as a therapeutic agent, it might not just slow tumors but restore the immune system's capacity to respond to existing drugs. The researchers emphasize that much work remains. The findings come from mouse models and human cell samples, not from people receiving treatment. Different cancers may respond differently. And thymulin's effects in the complex environment of a living human body remain unknown. But the pathway is clear enough that clinical trials seem like a logical next step—a way to test whether restoring a hormone that naturally declines with age might help older adults fight cancer more effectively.